This segment focuses on the research, development, and clinical trials of small-molecule product candidates for the treatment of non-alcoholic steatohepatitis (NASH). Terns is developing TERN-101, a liver-distributed FXR agonist, currently in Phase IIa trials. TERN-201, a VAP-1 inhibitor, is in Phase Ib trials. The company utilizes advanced drug discovery techniques and clinical trial methodologies to address the significant unmet medical need in NASH. The goal is to improve liver health and reduce the progression of the disease. Market positioning is based on the potential to offer effective oral therapies. Future opportunities include expanding the pipeline and securing regulatory approvals. This segment is subject to rigorous clinical trial protocols and FDA regulations, and involves collaborations with research institutions and pharmaceutical partners.

This segment is dedicated to the development of therapies for obesity and metabolic diseases. The primary focus is on TERN-601, a small-molecule GLP-1 receptor agonist, designed for oral administration. Research and development activities include preclinical studies, formulation development, and clinical trials. The company leverages its expertise in small-molecule drug development to create effective and safe treatments. The therapeutic area is obesity, with the aim of improving metabolic health and addressing related comorbidities. Market positioning is based on the growing demand for effective obesity treatments. Future opportunities include expanding the product pipeline and securing regulatory approvals. This segment is subject to clinical trial regulations and involves potential partnerships with obesity research organizations and pharmaceutical companies.

This segment focuses on the development of TERN-501, a thyroid hormone receptor beta (THR-β) agonist, for the treatment of NASH. The research and development activities include preclinical studies, Phase I clinical trials, and formulation development. The company utilizes its expertise in small-molecule drug development to create effective and safe treatments. The therapeutic area is NASH, with the aim of improving liver health and addressing related comorbidities. Market positioning is based on the potential to offer effective oral therapies. Future opportunities include expanding the product pipeline and securing regulatory approvals. This segment is subject to rigorous clinical trial protocols and FDA regulations, and involves collaborations with research institutions and pharmaceutical partners.